drugset / Trial / NCT03679767
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Timeline
- Start
- 2019-01-09
- Primary completion
- 2021-04-15
- Completion
- 2022-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |